Pancreatic Prediagnostic Imaging Repository

Abbreviated Name
Pancreatic Prediagnostic Imaging Repository
Lead Investigator
Maitra, Anirban — The University of Texas M D Anderson Cancer Center
Coordinating Investigator
Zheng, Yingye — Fred Hutchinson Cancer Center
Involved Investigators

Abstract

Progress in the management of pancreatic ductal adenocarcinoma (PDAC) has been limited in comparison to declines in cancer-related deaths seen in other malignancies (i.e., lung and bronchus, breast, colorectal and prostate cancer). The incidence of cancer-related deaths due to PDAC continues to rise (1). Early detection of PDAC is unusual and typically incidental, with the majority of patients (~85%) presenting with locally advanced or metastatic disease. Overall, PDAC is associated with a dire prognosis, and a 5-year survival rate of only 4% (2). Recent exome analyses on PDAC patients who have undergone a “warm” autopsy has shown that the genetic timeline for progression of this disease from initiation to terminal metastases is nearly two decades. These data suggest a substantial window of opportunity for early detection (3). Early detection of PDAC is an area of significant interest and represents an unmet need for the clinical and research community.

Aims

1. Establish a multi-institutional imaging repository for pre-diagnostic and early pancreatic cancer cases with clinical annotation. 2. Validate quantitative imaging tools for early detection of pancreatic cancer.

Analytic Method

No analytic method available.

Outcome

Progress in the management of pancreatic ductal adenocarcinoma (PDAC) has been limited in comparison to declines in cancer-related deaths seen in other malignancies (i.e., lung and bronchus, breast, colorectal and prostate cancer). The incidence of cancer-related deaths due to PDAC continues to rise (1). Early detection of PDAC is unusual and typically incidental, with the majority of patients (~85%) presenting with locally advanced or metastatic disease. Overall, PDAC is associated with a dire prognosis, and a 5-year survival rate of only 4% (2). Recent exome analyses on PDAC patients who have undergone a “warm” autopsy has shown that the genetic timeline for progression of this disease from initiation to terminal metastases is nearly two decades. These data suggest a substantial window of opportunity for early detection (3). Early detection of PDAC is an area of significant interest and represents an unmet need for the clinical and research community.

Publications

  • No publications available at this time for this protocol.

Biomarkers

  • No biomarkers available at this time for this protocol.

Data Collections

  • No data collections available at this time for this protocol.
Finish Date
Jun 30 2027
Protocol ID
543
Protocol Type
Reference Set
Fields of Research
  • Other
Collaborative Group
G.I. and Other Associated Cancers Research Group
Cancer Types
  • (No cancer types specified)

Associated Forms